Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Collegium Pharmaceutical (COLL) EBITDA Margin: 2016-2025

Historic EBITDA Margin for Collegium Pharmaceutical (COLL) over the last 10 years, with Sep 2025 value amounting to 29.66%.

  • Collegium Pharmaceutical's EBITDA Margin rose 779.00% to 29.66% in Q3 2025 from the same period last year, while for Sep 2025 it was 20.74%, marking a year-over-year decrease of 1155.00%. This contributed to the annual value of 26.91% for FY2024, which is 255.00% down from last year.
  • As of Q3 2025, Collegium Pharmaceutical's EBITDA Margin stood at 29.66%, which was up 58.82% from 18.67% recorded in Q2 2025.
  • In the past 5 years, Collegium Pharmaceutical's EBITDA Margin ranged from a high of 41.20% in Q4 2023 and a low of -124.71% during Q4 2021.
  • In the last 3 years, Collegium Pharmaceutical's EBITDA Margin had a median value of 26.29% in 2023 and averaged 26.14%.
  • In the last 5 years, Collegium Pharmaceutical's EBITDA Margin crashed by 14,437bps in 2021 and then spiked by 13,378bps in 2022.
  • Quarterly analysis of 5 years shows Collegium Pharmaceutical's EBITDA Margin stood at -124.71% in 2021, then skyrocketed by 13,378bps to 9.07% in 2022, then surged by 3,213bps to 41.20% in 2023, then plummeted by 2,025bps to 20.95% in 2024, then surged by 779bps to 29.66% in 2025.
  • Its EBITDA Margin stands at 29.66% for Q3 2025, versus 18.67% for Q2 2025 and 12.20% for Q1 2025.